Provided is a three dimensional tissue scaffold comprising a stem cell attracting element associated with a matrix, and fusion protein of stem cell attracting factor and collagen-binding domain, and methods of uses thereof.

A hybrid scaffold is disclosed which is made of materials that define peripheral layers designed to interface with the tissues in the implant site and one or more intermediate layers. The materials are combined to give the scaffold mechanical properties suitable for withstanding the stresses of the implant site. The materials are fibroin for the peripheral layers and polyurethane combined with fibroin for each intermediate layer.

Described embodiments are directed toward centrally-opening, leaflet valve devices and systems for transcatheter delivery having a two-piece valve body as well as methods of making and delivering the two-piece valve devices. A transcatheter valve includes a collapsed configuration and an expanded configuration. The transcatheter valve can further include an everted configuration and a non-everted configuration.

A vascular device for insertion in a body lumen, wherein the device includes a surface including at least a portion that is a functionalized surface provided with double or more charged ions such that the ions are exposed to a bodily fluid when the vascular device is inserted in the body lumen. The vascular device allows for reducing complications in its use and, particularly, for improving a desired healing in the body and preventing restenosis. At the same time, it allows for being manufactured at comparably low effort and for a convenient handling.

A prosthetic heart valve assembly includes a self-expandable stent having a flared upper portion, a lower portion, and an intermediate portion extending from the upper portion to the lower portion. The stent includes upwardly bent hooks extending from an outer surface of the stent, which are adapted to engage native leaflet tissue. The stent further includes an elongate anchoring member extending from the lower portion of the stent, which is adapted to be secured to a ventricle wall via a prong portion. When deployed within the native heart valve, the flared upper portion contacts a supra-annular surface of the native heart valve for preventing downward migration of the prosthetic heart valve assembly toward the ventricle and the upwardly bent hooks and the elongate anchoring member prevent upward migration of the prosthetic heart valve assembly toward an atrium.

Described embodiments are directed toward centrally-opening leaflet prosthetic valve devices having a leaflet frame and a mechanically coupled leaflet. The described leaflet frames have projections that are configured to couple with a leaflet attachment region of a leaflet. Some embodiments include a leaflet retention feature that engages the leaflet frame projections and operates to secure the leaflet to the leaflet frame. Methods of making and using such prosthetic valve devices are also described.

A bioprosthetic valve and a preparation method thereof are provided. The bioprosthetic valve includes a stent and a functional biological tissue material attached to the stent. The functional biological tissue material is a biologicaltissue covalently bonded with an active group and a functional molecule or group. The method improves the anti-thrombosis and anti-calcification functions by covalently modifying the surface of a biological valve using an active group and a functional molecule or group with a substantial degree of grafting. The new bioprosthetic valve does not include aldehyde residues, exhibits excellent biocompatibility, optimal mechanical properties, high stability, and can meet the performance requirements of a biological valve delivered through a catheter.

Devices are disclosed for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the mitral valve and an edge to edge device. Methods are disclose for reducing mitral valve regurgitation at low left ventricle pressure and high left ventricle pressure during the cardiac cycle. Devices are disclosed for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation assistance element for implantation across the mitral valve with an adaptive coaptation element.

Provided are a pro-endothelialization biological material and method for preparation thereof, and a pro-endothelialization heart valve and method for preparation thereof and interventional system. The pro-endothelialization biological material comprises a biological material and a pro-endothelializing growth factor loaded on the surface of biological material; capable of capturing endothelial progenitor cells, enabling the endothelial progenitor cells to attach, grow, and differentiate on the surface of the biological material. The methods for preparation of the pro-endothelialization biological material comprises chemical grafting and physical coating methods. The heart valve can be prepared either by suturing followed by grafting or by grafting followed by suturing. A endothelial growth factor is directly loaded onto the surface of a biological material film, promoting the formation of endothelial cell layers on the surface of the biological material.

A biological material is provided and prepared by performing (a) oxidation, (b) first cross-linking, (c) second cross-linking, and (d) dehydration on a biological material for preparation; wherein (b) is performed after (a), and (a), (b), and (c) are all performed prior to (d); during oxidation, an oxidizing agent able to cause hydroxy groups to be converted to aldehyde groups is utilized, the hydroxy groups coming from mucopolysaccharides in the biological material; during first cross-linking, a first cross-linking agent able to cause cross-linking between aldehyde groups of mucopolysaccharides is utilized; and during second cross-linking, a second cross-linking agent able to cause cross-linking between collagen fibers in the biological material is utilized.